Navigation Links
Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis

rous autoimmune diseases with an initial indication targeting refractory relapsing-remitting Multiple Sclerosis. Revimmune is based on pulsed, ultra-high dosing of a well-known chemotherapeutic agent under a risk management program. Additionally, through an investment strategy, the Company has acquired the majority ownership interest in Biovest International, Inc. ("Biovest"), (BVTI.OB) and a royalty interest in Biovest's lead drug candidate, BiovaxID(TM) and any other biologic products developed by Biovest. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. In addition to these product candidates, the Company has a specialty pharmaceutical business which markets products focused on respiratory disease and an analytical consulting business that serves customers in the biopharmaceutical industry. For further information, visit the Company Web site at www.accentia.net.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Revimmune(TM) SinuNase(TM), BiovaxID(TM), AutovaxID(TM), CRSFungal Profile(TM) and any other statements relating to products, product candidates, product development programs the FDA or clinical study process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and oth
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:8/27/2014)... Ltd. (NASDAQ: SVA ), a leading provider of biopharmaceutical ... of the Company,s 2014 Annual General Meeting of Shareholders held on ... The required quorum, a majority of the common shares outstanding, was ... following proposals:  , The re-election of Weidong Yin ... Kenneth Lee and Meng Mei as the Company,s ...
(Date:8/27/2014)... YORK and LONDON , Aug. 27, ... research solutions, MarketResearch.com is pleased to announce the ... Medical Devices Knowledge Center. The Medical ... the latest market research in the healthcare industry. ... reports from industry expert, Kalorama Information, published from ...
(Date:8/26/2014)... -- Intelomed is pleased to announce that Mary ... the Vice President of Clinical Affairs. With over 30 ... industry, Kay,s experience in taking medical technology and associated ... global expansion, is a valuable addition to the Intelomed ... our team, and I am confident her focused and ...
Breaking Medicine Technology:Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2
(Date:8/27/2014)... 27, 2014 Will Holbrook, CP LP, ... Will has over 15 years of experience in the ... Rome, Georgia with a Bachelor of Science degree with ... He received his graduate degree in prosthetics at ... to have Will join us at Fourroux,” says Keith ...
(Date:8/27/2014)... (HealthDay News) -- In a new study done from ... your blood pressure steadily increases if you ascend to ... widely used to treat high blood pressure was ineffective ... findings, reported online Aug. 27 in the European ... but those at sea level who have sleep apnea, ...
(Date:8/27/2014)... BESLER Consulting , a leading provider of ... pleased to announce that it has been named to ... The list represents the most comprehensive look at an ... "It's been an exciting year for our company and ... Inc. 5000 list,” said Jonathan Besler, BESLER’s President and ...
(Date:8/27/2014)... IL (PRWEB) August 27, 2014 The ... announce the recipients of the 2014-2016 Basic Research Fellowships ... early career scientists, the ABTA is seeding the field ... to change our understanding of the causes, effects, diagnosis ... selected by a scientific committee based on the potential ...
(Date:8/27/2014)... 2014) An experimental drug designed to help regulate the ... for anemia of inflammation, according to results from the first ... in Blood , the Journal of the ... condition that occurs when red blood cells are in short ... anemia, the body does not get enough oxygen, since there ...
Breaking Medicine News(10 mins):Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Drug represents first potential treatment for common anemia 2
... Aug. 13 Lilly MDR TB Partnership and Children International ... TB eradication in India. , , ... , Lilly MDR TB Partnership, with the support ... teen community with necessary resources to help reach out to ...
... to perceive feelings, study finds , THURSDAY, Aug. 13 ... to recognize other people,s facial emotions, a new study ... brain activity in 15 abstinent long-term alcoholics while they ... emotional expressions. The brain scans revealed decreased activation in ...
... treatment, prevention and detection behind progress, study finds , ... are declining, especially among younger people, new research shows. ... number one killer in the United States, topping heart ... decreased faster than for cancer. , "Older Americans have ...
... , , , , ... KAD ), a leading provider of home care, medical staffing, and pharmacy services ... ended June 30, 2009. , , For the ... with $26.8 million for the same period last year. Arcadia reported a ...
... , , New England ... Therapeutics Article; UFE Could Decrease Hysterectomy Rate in United States ... Uterine fibroid embolization--a minimally invasive interventional radiology treatment for women that ... highlighted as an appropriate treatment for women in a Clinical Therapeutics ...
... BALTIMORE, Aug. 13 To protect the health of ... and the Greater Baltimore Urban League have joined together to ... American Medical Association. , , In ... minorities, including African Americans, face significant barriers to health care, ...
Cached Medicine News:Health News:'Eli Lilly-Children International' Launches Teen Campaign to Reduce TB Cases in India 2Health News:'Eli Lilly-Children International' Launches Teen Campaign to Reduce TB Cases in India 3Health News:Boozing Blunts Ability to Read Faces 2Health News:Cancer Deaths Declining, Especially Among Young 2Health News:Cancer Deaths Declining, Especially Among Young 3Health News:Arcadia Resources Announces First Quarter Results 2Health News:Arcadia Resources Announces First Quarter Results 3Health News:Arcadia Resources Announces First Quarter Results 4Health News:Arcadia Resources Announces First Quarter Results 5Health News:Arcadia Resources Announces First Quarter Results 6Health News:Arcadia Resources Announces First Quarter Results 7Health News:Arcadia Resources Announces First Quarter Results 8Health News:Arcadia Resources Announces First Quarter Results 9Health News:Arcadia Resources Announces First Quarter Results 10Health News:Arcadia Resources Announces First Quarter Results 11Health News:Arcadia Resources Announces First Quarter Results 12Health News:Arcadia Resources Announces First Quarter Results 13Health News:Arcadia Resources Announces First Quarter Results 14Health News:Arcadia Resources Announces First Quarter Results 15Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 2Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 3Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 4Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 5Health News:Leading African American Groups Call On Health Insurers to Dismiss Restrictive Practices 2Health News:Leading African American Groups Call On Health Insurers to Dismiss Restrictive Practices 3
IDS Rapid NF Plus, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Bax detection system is a fast and accurate test for screening food and environmental samples by breaking them down to genetic level, using the power of the polymerase chain reaction (PCR) to detect ...
A versatile plate washer and/or dispenser that aspirates from the top down without immersing the aspirating tubes in the well, ensuring overflow protection. 5 programmable protocols....
Medicine Products: